Comparison of Ionis Pharmaceuticals Inc. (IONS) and Liquidia Technologies Inc. (NASDAQ:LQDA)

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Liquidia Technologies Inc. (NASDAQ:LQDA), both competing one another are Biotechnology companies. We will compare their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ionis Pharmaceuticals Inc. 752.47M 12.45 365.62M 0.51 137.95
Liquidia Technologies Inc. 1.78M 101.85 39.39M -2.25 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Ionis Pharmaceuticals Inc. and Liquidia Technologies Inc.

Profitability

Table 2 shows the net margins, return on assets and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Ionis Pharmaceuticals Inc. 48.59% -31.1% -8.7%
Liquidia Technologies Inc. -2,212.92% -813.3% -135.7%

Liquidity

The Current Ratio and Quick Ratio of Ionis Pharmaceuticals Inc. are 8 and 8 respectively. Its competitor Liquidia Technologies Inc.’s Current Ratio is 4.9 and its Quick Ratio is 4.9. Ionis Pharmaceuticals Inc. can pay off short and long-term obligations better than Liquidia Technologies Inc.

Analyst Recommendations

Ionis Pharmaceuticals Inc. and Liquidia Technologies Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Ionis Pharmaceuticals Inc. 0 2 1 2.33
Liquidia Technologies Inc. 0 0 0 0.00

Ionis Pharmaceuticals Inc. has an average target price of $68.33, and a 2.38% upside potential.

Insider & Institutional Ownership

Institutional investors held 89.1% of Ionis Pharmaceuticals Inc. shares and 53.1% of Liquidia Technologies Inc. shares. Ionis Pharmaceuticals Inc.’s share held by insiders are 0.2%. Comparatively, 1.7% are Liquidia Technologies Inc.’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Ionis Pharmaceuticals Inc. 14.3% 21.53% 21.62% 52.61% 33.45% 30.39%
Liquidia Technologies Inc. -10.3% 20.99% -23.61% 9.36% 0% -19.62%

For the past year Ionis Pharmaceuticals Inc. had bullish trend while Liquidia Technologies Inc. had bearish trend.

Summary

On 11 of the 12 factors Ionis Pharmaceuticals Inc. beats Liquidia Technologies Inc.

Ionis Pharmaceuticals, Inc. engages in discovering and developing RNA-targeted therapeutics. The company markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol, and as an adjunct to lipid lowering medications and diet. Its drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug to treat all forms of transthyretin amyloidosis. The company also develops IONIS-HTTRx, an antisense drug to treat patients with Huntington's disease; IONIS-SOD1Rx, an antisense drug to treat patients with an inherited form of amyotrophic lateral sclerosis; AKCEA-ANGPTL3-LRx, a LICA drug for treating multiple lipid disorders or mixed dyslipidemias; IONIS-PKKRx, an antisense drug that treats patients with hereditary angioedema; IONIS-FXIRx, an antisense drug for the treatment of thrombosis; AKCEA-APO(a)-LRx, a LICA drug that reduces apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); and AKCEA-APOCIII-LRx, an antisense drug for cardiometabolic disease. In addition, it develops IONIS-AR-2.5Rx, an antisense drug that treats patients with prostate cancer; IONIS-STAT3-2.5Rx, a cancer drug; AKCEA-ANGPTL3-LRx, a LICA drug to treat multiple lipid disorders; IONIS-GCGRRx, an antisense drug to treat patients with type 2 diabetes; and IONIS-DGAT2Rx, an antisense drug to treat patients with liver disease. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.

Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865, which completed Phase Ib clinical trials for the treatment of local post-operative pain. It has strategic collaboration agreements with GlaxoSmithKline plc and Aerie Pharmaecuticals, Inc. Liquidia Technologies, Inc. was incorporated in 2004 and is headquartered in Morrisville, North Carolina.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.